OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤$163.3 million cash and securities extend OnKure’s expected runway into 2029
- ➤OKI-355 IND submission for vascular anomalies planned in 1H 2027
- ➤OKI-345 IND submission for breast cancer planned in 1H 2027
- ➤Third-quarter net loss widened to $17.8 million from $14.7 million
- ➤PANORAMA registry launched to characterize vascular-anomaly disease course and treatment patterns
Expert Statements
Nicholas Saccomano, President and Chief Executive Officer of OnKure
“We continue to advance the development of next-generation PI3Kα pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027”
Samuel Agresta, Chief Medical Officer of OnKure
“People living with vascular anomalies remain underserved, and we believe OnKure has an opportunity to help shape the future of treatment for this community. Mutations in the PIK3CA gene drive a range of vascular malformations, providing a compelling rationale for our development of OKI-355, which is designed to provide broad coverage across these mutations. We are excited to build on that work with the introduction of PANORAMA, a large-scale observational registry designed to generate insights that may inform future research and treatment strategies. Together, these efforts reflect our commitment to addressing both the need for new therapies and the gaps in disease knowledge that can guide their development”
-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant-selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027
Get started
Create a free account to read the full story.